Integrated Filing — IndAS



General information about company

Scrip Code 539872
NSE Symbol BAJAJHCARE
MSEI Symbol NOTLISTED
ISIN INE411U01027
Name of company BAJAJ HEALTHCARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 17-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 09-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 17-10-2026   16:00:00
End date and time of board meeting 17-10-2026   16:24:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 11-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.bajajhealth.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
During the quarter ended 30th September 2026, there has been no default of any loan or debt securities.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 17,590.16 34,153.33
Other income 89.24 170.38
Total income 17,679.40 34,323.71
2 Expenses
(a) Cost of materials consumed 9,841.21 19,000.12
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (703.96) (1,253.20)
(d) Employee benefit expense 1,911.21 3,658.33
(e) Finance costs 597.53 1,206.63
(f) Depreciation, depletion and amortisation expense 764.94 1,466.32
(f) Other Expenses
1 Brokerage & Commission 162.20 264.02
2 Consumption of Stores Spares and Maintainence 434.69 1,107.94
3 Freight Forwarding & Transport 275.90 634.46
4 Legal & Professional Expenses 228.10 403.26
5 Material Testing & Inspection Charges 130.22 214.43
6 Power and Fuel 791.40 1,539.47
7 Processing & Labour Charges 581.82 1,162.81
8 Provision for Credit Loss 250.00 350.00
9 Repairs & Maintenance (Others) 94.94 148.27
10 Others 471.61 927.43
Total other expenses 3,420.88 6,752.09
Total expenses 15,831.81 30,830.29
3 Total profit before exceptional items and tax 1,847.59 3,493.42
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,847.59 3,493.42
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 409.61 666.16
9 Total tax expenses 409.61 666.16
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,437.98 2,827.26
12 Profit (loss) from discontinued operations before tax (38.19) (64.22)
13 Tax expense of discontinued operations (9.61) (16.16)
14 Net profit (loss) from discontinued operation after tax (28.58) (48.06)
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,409.40 2,779.20
17 Other comprehensive income net of taxes 22.45 44.90
18 Total Comprehensive Income for the period 1,431.85 2,824.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,683.26 1,683.13
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.27 8.4
Diluted earnings (loss) per share from continuing operations 4.26 8.38
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations -0.08 -0.14
Diluted earnings (loss) per share from discontinued operations -0.08 -0.14
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.19 8.26
Diluted earnings (loss) per share from continuing and discontinued operations 4.18 8.24
24 Debt equity ratio 48.00 48.00
25 Debt service coverage ratio 226.00 249.00
26 Interest service coverage ratio 409.00 390.0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above financial results of Bajaj Healthcare Limited (the Company) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 17 October 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion. 2. The above un audited financial results for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. 3. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. 4. In the year ended 31 March 2024, the Board of Directors had approved to saledisposal of undertakingunit(s) on going concern basis, situated at plot no. N 92, L 93, T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D2CH42 and D2CH43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E 62 and E 63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for saledisposal under Ind AS 105 (Non current Assets Held for Sale and Discontinued Operations). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and L 93 was sold during the Quarter ended 31 March 2026. The Company has sold a portion of its Plot No. D 2CH42 and D 2CH43 Dahej Industrial Area, GIDC, Bharuch, Gujarat in the current quarter. The total value of assets classified as held for sale represents lower of carrying value or fair value. The financial information from discontinued operations: Particulars Quarter Ended Period ended Year ended 30 Sept 2026 30 June 2026 30 Sept 2025 30 Sept 2026 30 Sept 2025 31 March 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Total Income ( A ) 75.35 0.05 75.35 2.15 11.71 Total Expenses ( B ) 113.54 26.03 179.05 139.57 226.58 523.40 Loss before Tax from Discontinued Operations ( C = A B ) (38.19) (26.03) (179.00) (64.22) (224.43) (511.69) Tax Credit from Discontinued Operations ( D ) (9.61) (6.55) (45.06) (16.16) (56.49) 42.74 Loss after Tax from Discontinued Operations ( E = C D ) (28.58) (19.48) (133.94) (48.06) (167.94) (554.43) Subsequent to the quarter ended 30 September 2026, the Company has completed its sale of Plot No. D 2CH42 and D 2CH43 Dahej Industrial Area, GIDC, Bharuch, Gujarat. 5. On 23 June 2026, the Board of Directors of the Company approved the sale of its unit at Plot No. N 178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar 401 506 with an unrelated party. The expected timeline for conclusion of Sale transaction is 31 October 2026. Hence, the unit has been classified as Property Held for Sale as at 30 September 2026. 6. During the financial year ended 31 March 2025, the Company allotted 39,84,852 equity shares and 20,79,409 convertible warrants on a preferential basis, raising an aggregate amount of Rs. 20,497.00 lakhs. The consideration for the equity shares was received in September 2024, and the shares were allotted in the same month. Further, 25 of the issue price of the convertible warrants was received in September 2024, and the balance 75 was received in March 2026. Subsequently, in March 2026, the Company approved the conversion of all 20,79,409 convertible warrants into an equivalent number of fully paid up equity shares of face value Rs. 5 each. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities: Particulars Amount to be Utilised Utilised up to 30 Sept 2026 Unutilised Balance Repayment of loan 15,000.00 15,000.00 Investment in capital expenditure 3,500.00 2,912.48 587.52 General corporate purposes 1,997.00 1,993.48 3.52 Total 20,497.00 19,905.96 591.04 7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) (Genrx), an existing company incorporated under the provisions of the Companies Act, 1956, on a going concern basis for a total consideration of Rs.1,085.00 lakhs. Subsequently, on 3 June 2025, the Company filed an application before the Honble National Company Law Tribunal (NCLT), Mumbai Bench, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern. The said application remained pending before the NCLT as on 30 September 2026. Accordingly, Genrx has not been considered a subsidiary of the Company for consolidation purposes, as control, as defined under Ind AS 110, Consolidated Financial Statements, had not been established as at the reporting date. However, on 13 October 2026, the Company received an order from the Honble NCLT approving the acquisition of Genrx on a going concern basis. Pursuant to the aforesaid order, Genrx Pharmaceuticals Private Limited will become a wholly owned subsidiary of Bajaj Healthcare Limited, subject to the implementation of the terms and conditions specified in the order passed by the Honble NCLT and the completion of the applicable procedural and legal formalities.



Remarks

Debt equity ratio Debt Equity Ratio is 0.48
Debt service coverage ratio DSCR is 2.49 for the half year ended 30 SEP 2026
Interest service coverage ratio DSCR is 3.90 for the half year ended 30 SEP 2026


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 22,837.53
Capital work-in-progress 1,066.49
Investment property 0.00
Goodwill 0.00
Other intangible assets 640.29
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 2.02
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Fixed deposits with remaining maturity more than 12 months 238.49
2 Amount paid for Investment in Genrx Pharma 1,085.00
Total of other non-current financial assets 1,323.49
Total non-current financial assets 1,325.51
Deferred tax assets (net) 399.91
Other non-current assets
1 Capital Advances 4,183.76
2 Non current tax Assets (Net) 439.91
3 Right of Use Assets 2,781.12
Total of other non-current assets 7,404.79
Total non-current assets 33,674.52
2 Current assets
Inventories 23,653.40
Current financial asset
Current investments 0.00
Trade receivables, current 25,162.53
Cash and cash equivalents 1,347.32
Bank balance other than cash and cash equivalents 74.67
Loans, current 0.00
Other current financial assets
Total of other current financial assets 846.37
Total current financial assets 27,430.89
Current tax assets (net) 0.00
Other current assets
1 Balance with Statutory Authority 3,696.47
2 Deposit With Public Authorities and Others 795.94
3 Prepaid Expenses 1,409.65
4 Advance to Suppliers 241.88
Total of other current assets 6,143.94
Total current assets 57,228.23
3 Non-current assets classified as held for sale 7,212.06
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 98,114.81
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,683.26
Other equity 54,032.85
Total equity attributable to owners of parent 55,716.11
Non controlling interest
Total equity 55,716.11
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 7,038.06
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 1,094.52
Total of other non-current financial liabilities 1,094.52
Total non-current financial liabilities 8,132.58
Provisions, non-current 807.85
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Nil 0.00
Total of other non-current liabilities 0.00
Total non-current liabilities 8,940.43
Current liabilities
Current financial liabilities
Borrowings, current 19,713.71
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 452.56
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 10,694.85
Total Trade payable 11,147.41
Other current financial liabilities
1 Employee related liability 557.29
2 Security Deposit received 30.00
3 Other Payables 522.89
4 Lease Liabillities 319.96
Total of other current financial liabilities 1,430.14
Total current financial liabilities 32,291.26
Other current liabilities 116.38
1 Statutory Dues Payable 116.38
Total of other current liabilities 116.38
Provisions, current 32.22
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 32,439.86
3 Liabilities directly associated with assets in disposal group classified as held for sale 1,018.41
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 42,398.70
Total equity and liabilites 98,114.81
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plans 30.00 60.00
Total Amount of items that will not be reclassified to profit and loss 30.00 60.00
2 Income tax relating to items that will not be reclassified to profit or loss 7.55 15.10
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 22.45 44.90



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,493.42
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,206.63
Adjustments for decrease (increase) in inventories (2,052.44)
Adjustments for decrease (increase) in trade receivables, current (2,153.59)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,072.72)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (380.58)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 964.30
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,466.32
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 350.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (118.75)
Adjustments for dividend income 0.00
Adjustments for interest income 16.38
Adjustments for share-based payments 96.63
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (160.10)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,870.68)
Net cash flows from (used in) operations 1,622.74
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 54.07
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 1,568.67
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 756.02
Purchase of property, plant and equipment 6,096.25
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 16.38
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.52
Net cash flows from (used in) investing activities (5,323.33)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.13
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 4,503.31
Repayments of borrowings 1,270.38
Payments of lease liabilities 205.55
Dividends paid 504.98
Interest paid 1,144.09
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 1,378.44
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (2,376.22)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (2,376.22)
Cash and cash equivalents cash flow statement at beginning of period 3,723.54
Cash and cash equivalents cash flow statement at end of period 1,347.32





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Others
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 18-03-2026
Amount Raised 5,271.30
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment & Prepayment of Secured/Unsecured Loans from Bank/NBFC in part or in full Not Applicable 15,000.00 15,000.00 15,000.00 0.00
2 Investment in Capital Expenditure Not Applicable 3,500.00 3,500.00 2,912.48 0.00
3 General Corporate Purpose Not Applicable 2,200.00 1,997.00 1,993.48 0.00


Signatory Details

Name of signatory Rohan Parekh
Designation of person Chief Financial Officer
Place Thane
Date 17-10-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Bajaj Healthcare Limited Mr. Sajankumar Rameshwarlal Bajaj Chairman & Managing Director Remuneration NA 237.48 0.00 0.00
2 Bajaj Healthcare Limited Mr. Anil Champalal Jain Managing Director Remuneration NA 199.98 0.00 0.00
3 Bajaj Healthcare Limited Ms. Namrata Sajankumar Bajaj Whole-Time Director Remuneration NA 26.99 0.00 0.00
4 Bajaj Healthcare Limited Mr. Pakshal Anil Jain Whole-Time Director Remuneration NA 27.03 0.00 0.00
5 Bajaj Healthcare Limited Mrs. Harshavi Pakshal Jain Relative of Director Remuneration 20.00 Approved by the Audit Committee 9.56 0.00 0.00
6 Bajaj Healthcare Limited Mrs. Khushi Jain Relative of Director Any other transaction Legal & Professional Fees 12.00 Approved by the Audit Committee 3.60 1.80 0.00
7 Bajaj Healthcare Limited Mrs. Nihita Bajaj Kumar Relative of Director Any other transaction Legal & Professional Fees 24.00 Approved by the Audit Committee 12.00 0.00 0.00
8 Bajaj Healthcare Limited Taradevi Rameshwarlal Bajaj Charitable Trust Charitable Trust Any other transaction CSR Expenses 100.00 Approved by the Audit Committee 0.00 0.33 0.33
9 Bajaj Healthcare Limited Genrx Pharmaceuticals Private Limited Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives Any other transaction Operating Expenses incurred by Bajaj on behalf of Genrx Pharmaceuticals 500.00 Approved by the Audit Committee 87.88 103.62 191.50
10 Bajaj Healthcare Limited Bajaj Sindhudurg Rice Mills Limited Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives Any other transaction Repayment of Advance 100.00 Approved by the Audit Committee 10.00 18.52 8.52
Total value of transaction during the reporting period 614.52